CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
View All Press
